Okada, Yosuke

Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation

Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J. D., & Hurley, M. M. (2000) · Journal of Clinical Investigation

Bone Metabolism and DiseasesBone health and osteoporosis research

Cited by 483

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial

Ueki, K., Sasako, T., Okazaki, Y., Kato, M., Okahata, S., Katsuyama, H., Haraguchi, M., Morita, A., Ohashi, K., Hara, K., et al. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 313

Advanced Glycation End Products Induce Calcification of Vascular Smooth Muscle Cells through RAGE/p38 MAPK

Tanikawa, T., Okada, Y., Tanikawa, R., & Tanaka, Y. (2009) · Journal of Vascular Research

Advanced Glycation End Products researchParathyroid Disorders and Treatments

Cited by 191

Advanced glycation end products increase endothelial permeability through the RAGE/Rho signaling pathway

Hirose, A., Tanikawa, T., Mori, H., Okada, Y., & Tanaka, Y. (2010) · FEBS Letters

Advanced Glycation End Products researchBarrier Structure and Function Studies

Cited by 129

Anti-PD-1 Antibody Therapy Induces Hashimoto’s Disease with an Increase in Peripheral Blood Follicular Helper T Cells

Torimoto, K., Okada, Y., Nakayamada, S., Kubo, S., & Tanaka, Y. (2017) · Thyroid

Thyroid Disorders and TreatmentsAutoimmune Neurological Disorders and Treatments

Cited by 20